Trial Profile
A open-label, multicenter study to evaluate the efficacy of low-dose Eltrombopag in Taiwanese patients with chronic refractory immune thrombocytopenic purpura
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2016
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Therapeutic Use
- 12 Apr 2016 New trial record